Poster: ABCL-023 frontMIND: A Phase III, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma
Clinical Lymphoma Myeloma and Leukemia（2022）
关键词
ABCL,DLBCL,Phase III,R-CHOP,frontMIND,lenalidomide,tafasitamab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要